Topic

is head of external affairs and ESG at Organon. In this role, she focuses on guiding and shaping how the company interacts with key stakeholders and the environment.

Articles

The validity of ESG-driven investment and reporting in healthcare.

Is ESG a ‘Protection Racket’ or Long-Term Value Contributor?

Dr. Pamela Walker is Global Head of Health at Kin + Carta Advise.

A prime opportunity for pharma to raise its strategic game in ESG.

ESG: Applying  Lessons From Consumer Market 

U.S. patent law will have to adapt to the use of AI in the life sciences industry.

As Pharma Continues to Adapt to AI, the POSA Standard will Need to Equally Adapt

How principles of both can help companies navigate future storms.

Meeting the Moment: ESG Strategy and the Business of Resilience

Partner at Neal Gerber Eisenberg, specializing in life sciences intellectual property.

Intellectual Property Considerations for Drug Discovery Via Artificial Intelligence

Partner with IP law firm MBHB and the co-chair of its biotechnology and pharmaceuticals practice group

Issue represents a potential threat in fighting future pandemics.

The True Nature of Danger Behind IP Waiver Proposal

Pharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.

In DOJ Crosshairs: Rethinking Commission-Based  Deals With Independent Contractors

Instead, incorporate ESG into your long-term business planning.

Why You Don’t Need a Dedicated ESG Strategy

Lisa Henderson is the group editorial director of 

 and can be reached at lhenderson@mjhlifesciences.com.

Role drift and clinical trials among many areas for compliance professionals to keep an eye on in 2022.

Insights from Informa’s Pharmaceutical Compliance Congress 

Cross-sector businesses are banding together to protect their intellectual property, but there’s a better way to do it.


Legal